Investment Manager and Director of the Brainomix Board
Oliver brings venture capital and board experience from roles at Boehringer Ingelheim Venture Fund, High-Tech Gründerfonds, and multiple portfolio companies.
Niklas serves as an executive director and investment manager at the Boehringer Ingelheim Venture Fund, alongside his role as a clinical pharmacology and safety science lead. He also brings board experience from Refoxy Pharma, GLOX Therapeutics, and Obulytix.
The Series C round was co-led by Parkwalk Advisors and the Boehringer Ingelheim Venture Fund to support international expansion and clinical studies.
"We would like to thank all the investors that participated, including Parkwalk and Boehringer Ingelheim Venture Fund for their continued support, and welcome Hostplus, all of whom recognise the transformative impact that our technology can have on treatment for stroke and lung fibrosis patients. We will continue to harness our position and experience as a European market leader to achieve broad success in the US, helping improve patient care and access to life-changing therapies."
The seed round was co-led by Boehringer Ingelheim Venture Fund and Scottish Enterprise to support laboratory establishment and team expansion.
"Our mission is to provide physicians and patients with highly potent, targeted antimicrobial therapies that can kill antibiotic-resistant bacteria for which there are diminishing options available for treatment,"
The financing round was co-led by Boehringer Ingelheim Venture Fund and Parkwalk Advisors, with participation from Tencent and Oxford University Innovation Fund.
"Over the past decade Brainomix has created the market for stroke AI imaging. As a spin-out from the University of Oxford it is an example of the UK's world-leading strengths in life sciences and AI-enabled medtech, combining expertise in clinical care and software development with more than 150 years' experience in the field across its leadership team."
